Intrinsiqq
Pharmacyte Biotech Inc. logo

Pharmacyte Biotech Inc.

PMCB

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$43M
EPS-$2.40
P/E-1.65
P/FCF–
EV/EBITDA-3.54
FCF Yield–
Div. Yield–
Net Debt/FCF–
Pharmacyte Biotech Inc. intrinsic value
52-Week Range
$3.98$11.84

Profitability & Returns

Revenue (TTM)

$0.00

Net Income (TTM)

-$16M

▼ -163.4% YoY

Op. Margin

–

ROIC

-16.52%

▼ -4.0pp YoY

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

-$4M

▼ -73.0% YoY

Net Debt

-$18M

Net Cash Position

Cash & Equiv.

$18M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PMCB

CompareIntrinsic value
CSBRChampions Oncology, Inc.
$4.35-1.14%26
PLURPluri Inc.
$0.94-3.09%30
TECHBio-Techne Corporation
$72.67-0.04%41
OTLKOutlook Therapeutics Inc.
$0.39-3.32%10
SCLXScilex Holding Company
$0.57-12.95%0
ELUTElutia Inc.
$0.89+8.54%20
CRISCuris Inc.
$0.44-7.21%35
INBXInhibrx Biosciences, Inc.
$68.97-7.21%18

Pharmacyte Biotech (PMCB) in three numbers

Quality score
20/100
Best check: share count change, -44.9%. Weakest: return on capital, -16.5%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-1.65
Negative: a loss over the last twelve months.
Financials

Questions about Pharmacyte Biotech

Is Pharmacyte Biotech a high-quality business?

Pharmacyte Biotech scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is share count change at -44.9%, and its weakest is return on capital at -16.5%. The Quality tab shows every check against its target.

Does Pharmacyte Biotech (PMCB) pay a dividend?

No. Pharmacyte Biotech (PMCB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.9% buyback yield. The Dividends tab shows its cash returns.

Source: 10-Q filed 11 Sept 2026 (period ending 31 Jul 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in PMCB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PMCB

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.